News5 min read
Ozempic Blindness Warning: FDA Adds NAION Risk to All GLP-1s
The FDA's new Ozempic blindness warning covers every GLP-1, from Wegovy to Zepbound. What NAION is, how rare it is, and the symptoms to watch for.
What America is talking about today
Topic
The FDA's new Ozempic blindness warning covers every GLP-1, from Wegovy to Zepbound. What NAION is, how rare it is, and the symptoms to watch for.
Eli Lilly's Q3 2026 earnings beat estimates on $24.4 billion in revenue, and Lilly raised its 2026 sales outlook to $91-92 billion. What moved LLY stock.